Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA.
Toja-Camba FJ, García-Quintanilla L, Rodríguez-Martinez L, Tomine J, Cajade-Pascual F, Feitosa C, Zarra-Ferro I, Barreiro-De-Acosta M, González-López J, Mondelo-García C, Fernández-Ferreiro A. Toja-Camba FJ, et al. Pharmaceutics. 2023 Nov 11;15(11):2615. doi: 10.3390/pharmaceutics15112615. Pharmaceutics. 2023. PMID: 38004593 Free PMC article.
Longitudinal PET/CT evaluation of TNBS-induced inflammatory bowel disease rat model.
Seoane-Viaño I, Gómez-Lado N, Lázare-Iglesias H, Barreiro-de Acosta M, Silva-Rodríguez J, Luzardo-Álvarez A, Herranz M, Otero-Espinar F, Antúnez-López JR, Lamas MJ, Aguiar P, Fernández-Ferreiro A, Ruibal Á. Seoane-Viaño I, et al. Int J Pharm. 2018 Oct 5;549(1-2):335-342. doi: 10.1016/j.ijpharm.2018.08.005. Epub 2018 Aug 3. Int J Pharm. 2018. PMID: 30081226
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.
Gómez-Labrador C, Ricart E, Iborra M, Iglesias E, Martín-Arranz MD, de Castro L, De Francisco R, García-Alonso FJ, Sanahuja A, Gargallo-Puyuelo CJ, Mesonero F, Casanova MJ, Mañosa M, Rivero M, Calvo M, Sierra-Ausin M, González-Muñoza C, Calvet X, García-López S, Guardiola J, Arias García L, Márquez-Mosquera L, Gutiérrez A, Zabana Y, Navarro-Llavat M, Lorente Poyatos R, Piqueras M, Torrealba L, Bermejo F, Ponferrada-Díaz Á, Pérez-Calle JL, Barreiro-de Acosta M, Tejido C, Cabriada JL, Marín-Jiménez I, Roncero Ó, Ber Y, Fernández-Salazar L, Camps Aler B, Lucendo AJ, Llaó J, Bujanda L, Muñoz Villafranca C, Domènech E, Chaparro M, Gisbert JP. Gómez-Labrador C, et al. Pharmaceutics. 2024 May 8;16(5):629. doi: 10.3390/pharmaceutics16050629. Pharmaceutics. 2024. PMID: 38794292 Free PMC article.
Targeted 1H NMR metabolomics and immunological phenotyping of human fresh blood and serum samples discriminate between healthy individuals and inflammatory bowel disease patients treated with anti-TNF.
Notararigo S, Martín-Pastor M, Viñuela-Roldán JE, Quiroga A, Dominguez-Munoz JE, Barreiro-de Acosta M. Notararigo S, et al. J Mol Med (Berl). 2021 Sep;99(9):1251-1264. doi: 10.1007/s00109-021-02094-y. Epub 2021 May 21. J Mol Med (Berl). 2021. PMID: 34021361 Free PMC article.
Radon exposure and inflammatory bowel disease in a radon prone area.
Mauriz-Barreiro V, Barreiro-de Acosta M, Bastón-Rey I, Ferreiro-Iglesias R, Calviño-Suárez C, Barros-Dios JM, Domínguez-Munoz JE, Ruano-Raviña A. Mauriz-Barreiro V, et al. Rev Esp Enferm Dig. 2022 Jul;114(7):405-409. doi: 10.17235/reed.2021.8239/2021. Rev Esp Enferm Dig. 2022. PMID: 34781685
260 results